Skin acts as the first line of defense against pathogens and other harmful material from outside the body. Yet this barrier also excludes some beneficial drugs that could treat skin diseases. Now, researchers have taken the first steps in developing a chemotherapy for melanoma that can be “painted” directly on the skin, rather than injected or taken orally.
They report their results in ACS Nano.
According to the Skin Cancer Foundation, melanoma is the deadliest form of cancer because of its tendency to spread, or metastasize, from the skin to other parts of the body. Common treatments include surgery, radiation therapy and intravenous chemotherapy, but these can cause pain or unpleasant side effects. If scientists could find a way to administer chemotherapy through the skin, they could target the treatment directly to the tumor site and possibly avoid side effects. Bingfang He, Ran Mo and colleagues wanted to develop a gel that patients themselves could apply to a skin tumor. But first they had to figure out how to get the therapy to penetrate deep within the skin.
For this purpose, the researchers assembled nanoparticles called “transfersomes,” which consist of a phospholipid bilayer and surfactants that encapsulate drugs or other molecules — in this case, the chemotherapy drug paclitaxel. The surfactants made the particles more deformable so that they could better infiltrate the skin; these compounds also affected the lipid matrix of the skin to help the particles more easily pass. The researchers added a peptide to the surface of the transfersome to further help the particle penetrate the skin, as well as enter tumor cells. To increase the time that the transfersomes persisted on skin, the researchers embedded the nanoparticles into a hydrogel. Then, they painted the gel on tumors of melanoma-bearing mice once a day, in combination with intravenous administration of paclitaxel every other day. After 12 days, the tumors of these mice were about half the size of tumors in mice treated with intravenous paclitaxel alone, suggesting that the transfersome gel helped slow tumor growth.
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Melanoma New Zealand appoints new chief executive on December 16, 2018 at 5:31 pm
Melanoma New Zealand has announced the appointment of Andrea Newland as its new Chief Executive. Ms Newland will take up the role from 30th January 2019. Ms Newland will continue to build on Melanoma ... […]
- Melanoma Tasmania founder Di Mason calls for free skin checks, extra support on December 16, 2018 at 1:17 pm
It was the Christmas season 15 years ago when Melanoma Tasmania founder Di Mason found herself nursing her mother during a quick and unexpected death. Her mother, Judy, sought medical attention for a ... […]
- Idera’s TLR9-Yervoy combo sees ‘impressive’ disease control in PD-1-refractory melanoma on December 14, 2018 at 6:48 am
After reporting positive phase 1 results suggesting its TLR9 agonist tilsotolimod could work in synergy with CTLA4 inhibitor Yervoy in melanoma patients who progress on anti-PD-1, Idera Pharmaceutical... […]
- Combining three treatment strategies may significantly improve melanoma treatment on December 12, 2018 at 11:04 am
Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0 A study by a team led by a Massachusetts General Hospital (MGH ... […]
- Cancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma on December 12, 2018 at 10:00 am
When Amgen’s cancer-killing virus Imlygic—also known as T-Vec—was approved by the FDA in late 2015, experts expected it would work best in combination strategies for melanoma. Now a team led by scient... […]
- OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO™ + KEYTRUDA® in Refractory Metastatic Melanoma on December 12, 2018 at 5:47 am
-- Previously reported partial responses have now reached six months in duration and one response now assessed as a complete response SAN DIEGO and PENNINGTON, N.J, Dec. 12, 2018 /PRNewswire/ -- OncoS... […]
- Role of Neoadjuvant Therapy for Melanoma on December 11, 2018 at 1:31 pm
Merrick I Ross, MD: So I’m going to implore the treating clinicians to not jump to resect this disease when a patient recurs after receiving adjuvant therapy. They need to be put on neoadjuvant studie... […]
- Essential Science: New drug combination could treat melanoma on December 9, 2018 at 7:32 pm
Rates of melanoma are increasing worldwide, making it increasingly a matter of medical importance. A new drug combination, which is effective against the skin cancer, could save millions of lives each ... […]
- Uveal Melanoma-Market Insights Epidemiology and Market Forecast-2027 on December 7, 2018 at 9:38 am
According to National Cancer Institute, Uveal Melanoma is the most common intraocular malignancy and arises from melanocytes in the iris (anterior), ciliary body, or choroid (posterior). Iris melanoma... […]
via Bing News